IASO Biotherapeutics Application for Clinical Trials of the Second Indication of its Fully Human CD19/CD22 Dual-targeted CAR-T Drug Accepted by NMPA

PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)-- #Biopharmaceutical--IASO Biotherapeutics Application for Clinical Trials of the Second Indication of its Fully Human CD19/CD22 Dual-targeted CAR-T Drug Accepted by NMPA

Click to view original post